# Predictive factors and pharmacological preventive interventions for atrial fibrillation after aortic valve replacement

**Authors:** Lu Chen, Yu Liu, Junmei Ge

PMC · DOI: 10.1186/s13019-025-03577-6 · Journal of Cardiothoracic Surgery · 2025-08-09

## TL;DR

This study identifies risk factors for atrial fibrillation after heart valve surgery and shows that a drug combination can reduce its occurrence and hospital stay.

## Contribution

The study introduces a combined atorvastatin and metoprolol treatment as a preventive intervention for postoperative atrial fibrillation.

## Key findings

- Age, stroke history, EuroSCORE II, NT-proBNP, hs-CRP, and operation time predict postoperative atrial fibrillation.
- Combined atorvastatin and metoprolol reduced POAF incidence and shortened hospital and ICU stays.
- The predictive model had high accuracy (AUC 0.952) and clinical utility across risk thresholds.

## Abstract

This study aims to investigate the predictive factors for postoperative atrial fibrillation (POAF) following aortic valve replacement (AVR) and evaluate the preventive effect of combined atorvastatin and metoprolol therapy on POAF.

This study employed a mixed design of retrospective cohort analysis and prospective randomized controlled trial, including 268 patients who underwent isolated AVR from January 1, 2022, to March 31, 2024. The 168 patients from January 1, 2022, to May 31, 2023, were analyzed for POAF predictive factors, while 100 patients from June 1, 2023, were included in the prospective trial. The intervention group (n = 50) received combined atorvastatin and metoprolol treatment starting 7 days before surgery.

Multivariate logistic regression analysis identified age (OR = 1.12, 95% CI: 1.04–1.20, p = 0.003), history of stroke (OR = 10.94, 95% CI: 1.32–90.66, p = 0.027), EuroSCORE II (OR = 2.90, 95% CI: 1.61–5.20, p < 0.001), NT-proBNP level (OR = 1.002, 95% CI: 1.001–1.004, p = 0.009), hs-CRP level (OR = 1.55, 95% CI: 1.16–2.07, p = 0.003), and operation time (OR = 1.02, 95% CI: 1.01–1.04, p = 0.008) as independent predictors of POAF. Pharmacological intervention significantly reduced POAF incidence (p = 0.005) and shortened hospital stay (p < 0.001), ICU stay (p = 0.002), and mechanical ventilation time (p < 0.001). The AUC of the predictive model was 0.952, with a calibrated C-statistic of 0.904. Decision curve analysis demonstrated significant clinical utility across multiple risk thresholds.

Age, history of stroke, EuroSCORE II, NT-proBNP and hs-CRP levels, and operation time are independent predictors of POAF. Combined preventive treatment with atorvastatin and metoprolol reduced POAF incidence and postoperative hospital stay, showing promising clinical application prospects.

## Linked entities

- **Chemicals:** atorvastatin (PubChem CID 60823), metoprolol (PubChem CID 4171)
- **Diseases:** atrial fibrillation (MONDO:0004981), stroke (MONDO:0005098)

## Full-text entities

- **Diseases:** atrial fibrillation (MESH:D001281)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12335050/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12335050/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12335050/full.md

---
Source: https://tomesphere.com/paper/PMC12335050